Regentis Biomaterials Ltd. (RGNT)

Market Cap	31.85M
Revenue (ttm)	n/a
Net Income (ttm)	-333,000
Shares Out	5.18M
EPS (ttm)	-2.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,181
Open	6.34
Previous Close	6.05
Day's Range	6.13 - 6.34
52-Week Range	5.75 - 7.70
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About RGNT

Regentis Biomaterials Ltd., a regenerative medicine company, develops tissue repair solutions in the United States. The company offers orthopedic treatments using Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GelrinC, is a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. It offers Gelrin is a unique hydrogel matrix of polyethylene glycol diacrylat...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Dec 4, 2025
• Country: Israel
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: RGNT
• Website: https://www.regentis.co.il

Financial Performance

Financial numbers in USD